4.5 Article

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study

Journal

JOURNAL OF NEURO-ONCOLOGY
Volume 157, Issue 1, Pages 177-185

Publisher

SPRINGER
DOI: 10.1007/s11060-022-03960-6

Keywords

Diffuse astrocytoma; Diffuse astrocytic glioma; Glioma; Progression-free survival; Overall survival

Funding

  1. Mayo Clinic
  2. Florida State Department of Health Research Grant
  3. Mayo Clinic Graduate School
  4. NIH [R43CA221490, R01CA200399, R01CA195503, R01CA216855]
  5. FDA [R01 FD-R-07288]

Ask authors/readers for more resources

This study aimed to compare the survival outcomes between molecular GBM (molGBM) and histological GBM (histGBM). The results showed that molGBM had a longer progression-free survival (PFS) compared to histGBM, but similar overall survival (OS).
Purpose Histological diagnosis of glioblastoma (GBM) was determined by the presence of necrosis or microvascular proliferation (histGBM). The 2021 WHO classification now considers IDH-wildtype diffuse astrocytic tumors without the histological features of glioblastoma (that would have otherwise been classified as grade 2 or 3) as molecular GBM (molGBM, WHO grade 4) if they harbor any of the following molecular abnormalities: TERT promoter mutation, EGFR amplification, or chromosomal + 7/- 10 copy changes. The objective of this study was to explore and compare the survival outcomes between histGBM and molGBM. Methods Medical records for patients diagnosed with GBM at the three tertiary care academic centers of our institution from November 2017 to October 2021. Only patients who underwent adjuvant chemoradiation were included. Patients without molecular feature testing or with an IDH mutation were excluded. Univariable and multivariable analyses were performed to evaluate progression-free (PFS) and overall- survival (OS). Results 708 consecutive patients were included; 643 with histGBM and 65 with molGBM. Median PFS was 8 months (histGBM) and 13 months (molGBM) (p = 0.0237) and median OS was 21 months (histGBM) versus 26 months (molGBM) (p = 0.435). Multivariable analysis on the molGBM sub-group showed a worse PFS if there was contrast enhancement on MRI (HR 6.224 [CI 95% 2.187-17.714], p < 0.001) and a superior PFS on patients with MGMT methylation (HR 0.026 [CI 95% 0.065-0.655], p = 0.007). Conclusions molGBM has a similar OS but significantly longer PFS when compared to histGBM. The presence of contrast enhancement and MGMT methylation seem to affect the clinical behavior of this subset of tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available